CUMBERLAND PHARMACEUTICALS INCCPIXEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CPIX Q3 2025 Key Financial Metrics
Revenue
$8.3M
Gross Profit
$7.3M
Operating Profit
$-2.0M
Net Profit
$-1.9M
Gross Margin
88.1%
Operating Margin
-23.7%
Net Margin
-23.4%
YoY Growth
-8.7%
EPS
$-0.13
Financial Flow
CUMBERLAND PHARMACEUTICALS INC Q3 2025 Financial Summary
CUMBERLAND PHARMACEUTICALS INC reported revenue of $8.3M for Q3 2025, with a net profit of $-1.9M (-23.4% margin). Cost of goods sold was $988.8K, operating expenses totaled $9.3M.
Key Financial Metrics
| Total Revenue | $8.3M |
|---|---|
| Net Profit | $-1.9M |
| Gross Margin | 88.1% |
| Operating Margin | -23.7% |
| Report Period | Q3 2025 |
CUMBERLAND PHARMACEUTICALS INC Annual Revenue by Year
CUMBERLAND PHARMACEUTICALS INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $37.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $37.9M |
| 2023 | $39.6M |
| 2022 | $40.7M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.4M | $8.5M | $9.8M | $9.1M | $10.4M | $11.7M | $10.8M | $8.3M |
| YoY Growth | 20.0% | -7.9% | -9.6% | -9.9% | 11.6% | 37.8% | 10.0% | -8.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $81.8M | $81.5M | $78.5M | $76.7M | $75.6M | $69.9M | $67.9M | $65.9M |
| Liabilities | $52.5M | $54.3M | $52.5M | $52.3M | $53.0M | $41.6M | $40.2M | $40.1M |
| Equity | $29.6M | $27.5M | $26.3M | $24.8M | $22.9M | $28.7M | $28.0M | $26.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.0M | $-2.1M | $-855660 | $475503 | $1.9M | $3.9M | $843801 | $187180 |